首页> 美国卫生研究院文献>The Journal of Clinical Investigation >A Study of Angiotensin II Pressor Response throughout Primigravid Pregnancy
【2h】

A Study of Angiotensin II Pressor Response throughout Primigravid Pregnancy

机译:妊娠初孕期间血管紧张素II升压反应的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present study was designed to ascertain sequentially the pressor response to angiotensin II in young primigravid patients throughout pregnancy in order a) to define when in pregnancy resistance to the pressor effects of angiotensin II develops; b) to define the physiologic sequence of events leading to this resistance; and c) to ascertain whether sensitivity to infused angiotensin II could be detected before the onset of clinical signs of pregnancy-induced hypertension.With this prospective approach, two separate groups of patients were defined. The first group of patients remained normal throughout pregnancy. The second group consisted of those patients who, while clinically normotensive during the initial phase of the study, ultimately developed hypertension of pregnancy.192 patients were studied; of these, 120 patients remained normotensive and 72 developed pregnancy-induced hypertension. In both groups, vascular resistance to infused angiotensin II (more than 8 ng/kg/min required to elicit a pressor response of 20 mm Hg in diastolic pressure) was demonstrated as early as the 10th wk of pregnancy. In the group that remained normotensive, maximum mean vascular resistance occurred at 18-30 wk of pregnancy, (mean pressor dose required being 13.5 to 14.9 ng/kg/min). In those subjects who developed pregnancy-induced hypertension, the mean maximum dose required was 12.9 ng/kg/min, which was observed at the 18th wk of pregnancy. By the 22nd wk there was a clear separation of the two groups, with the mean dose requirement of the subjects destined to develop hypertension being progressively less than that of those who remained normal. The difference between the two groups became significant (P < 0.01) by 23-26 wk of pregnancy.Among patients requiring more than 8 ng/kg/min on one or more tests done between wk 28-32, 91% remained normotensive. Conversely, during the same time period among patients requiring less than 8 ng/kg/min, on at least one occasion, 90% developed pregnancy-induced hypertension.
机译:本研究旨在确定在整个妊娠期间年轻的初生妊娠患者中对血管紧张素II的升压反应,以便:a)定义在妊娠中何时出现对血管紧张素II的升压作用的抵抗力; b)确定导致这种抗药性的事件的生理顺序; c)确定在怀孕引起的高血压的临床体征发作之前是否可以检测到对输注的血管紧张素II的敏感性。采用这种前瞻性方法,将患者分为两组。第一组患者在整个怀孕期间保持正常。第二组包括在研究初期临床上血压正常但最终发展为妊娠高血压的患者。研究对象为192例患者。其中,120例患者保持血压正常,72例因妊娠引起的高血压。在两组中,早在怀孕的第10周就证明了对输注的血管紧张素II的血管抵抗力(引起舒张压中20 mm Hg的升压反应需要8 ng / kg / min以上)。在保持血压正常的组中,最大平均血管阻力发生在妊娠18-30 wk(所需的平均加压剂量为13.5至14.9 ng / kg / min)。在那些因妊娠引起的高血压的受试者中,所需最大平均剂量为12.9 ng / kg / min,这是在怀孕第18周时观察到的。到第22周时,两组之间已明显分开,注定要发展为高血压的受试者的平均剂量要求逐渐低于那些保持正常水平的受试者的平均剂量。两组之间的差异在怀孕23-26周时变得显着(P <0.01)。在28-32周之间进行一项或多项测试的患者中,要求超过8 ng / kg / min的患者中,仍有91%保持血压正常。相反,在同一时间段内,少于8 ng / kg / min的患者中,至少有90%发生了妊娠诱发的高血压。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号